Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Galen

Executive Summary

Branded generic Estrace (estradiol) tablets acquired by Galen from Bristol for $95 mil.; estrogen replacement therapy generated sales of $40.5 mil. in 2000. Bristol sold the U.S. rights to its Apothecon subsidiary's line of finished generic drugs to Novartis last year, but retained the branded generics (1"The Pink Sheet" Dec. 18, 2000, p. 5)

You may also be interested in...



Lilly Sells Sarafem: Galen Adds Drug To Women’s Health Line For $295 Mil.

Galen is adding Sarafem to its line of women's health products through a $295 mil. deal with Lilly

Lilly Sells Sarafem: Galen Adds Drug To Women’s Health Line For $295 Mil.

Galen is adding Sarafem to its line of women's health products through a $295 mil. deal with Lilly

Apothecon To Continue As Bristol Unit After Sale Of Generics To Novartis

Bristol Myers-Squibb will continue to market generic drugs internationally and its branded generics in the U.S. following the sale of U.S. rights to its Apothecon subsidiary's line of finished generic drugs to Novartis.

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel